Literature DB >> 12374692

Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen.

Hiroya Kobayashi1, Ryusuke Omiya, Marta Ruiz, Eduardo Huarte, Pablo Sarobe, Juan José Lasarte, Maite Herraiz, Bruno Sangro, Jesús Prieto, Francisco Borras-Cuesta, Esteban Celis.   

Abstract

PURPOSE: The product of the carcinoembryonic antigen (CEA) gene is an attractive candidate for T-cell-based immunotherapy because it is frequently expressed in epithelial solid carcinomas. Although many CEA peptide epitopes capable of stimulating CTLs have been identified, no MHC class II-restricted T helper epitope has yet been reported. EXPERIMENTAL
DESIGN: The amino acid sequence of CEA was examined for the presence of potential T helper epitopes, and candidate peptides were used to stimulate in vitro T-cell responses.
RESULTS: We describe here that using an algorithm to identify promiscuous helper T-cell epitopes, a peptide of CEA occupying residue positions 653 to 667 (CEA(653-667)), was effective in inducing in vitro T helper responses in the context of the HLA-DR4, HLA-DR7, and HLA-DR 9 alleles. Most significantly, some of the peptide-reactive helper T lymphocytes were also capable of recognizing naturally processed antigen in the form of recombinant CEA protein or cell lysates from tumors that express CEA. Interestingly, the newly identified helper T-cell epitope was found to overlap with a previously described HLA-A24-restricted CTL epitope, CEA(652-660), which could facilitate the development of a therapeutic vaccine capable of eliciting both CTL and T helper responses in patients suffering from epithelial carcinomas.
CONCLUSION: These results indicate that T helper lymphocytes are capable of recognizing CEA as a tumor antigen and that epitope CEA(653-667) could be used for immunotherapy against tumors expressing CEA.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12374692

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  16 in total

1.  Maturation of human dendritic cells with Saccharomyces cerevisiae (yeast) reduces the number and function of regulatory T cells and enhances the ratio of antigen-specific effectors to regulatory T cells.

Authors:  Vittore Cereda; Matteo Vergati; Ngar-Yee Huen; Maria Giovanna di Bari; Caroline Jochems; Chiara Intrivici; James L Gulley; David Apelian; Jeffrey Schlom; Kwong Y Tsang
Journal:  Vaccine       Date:  2011-05-11       Impact factor: 3.641

2.  A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver.

Authors:  James L Gulley; Ravi A Madan; Kwong-Yok Tsang; Philip M Arlen; Kevin Camphausen; Mahsa Mohebtash; Mitchell Kamrava; Jeffrey Schlom; Deborah Citrin
Journal:  Expert Opin Biol Ther       Date:  2011-08-28       Impact factor: 4.388

3.  In vitro peptide immunization of target tax protein human T-cell leukemia virus type 1-specific CD4+ helper T lymphocytes.

Authors:  Hiroya Kobayashi; Toshihiro Ngato; Keisuke Sato; Naoko Aoki; Shoji Kimura; Yuetsu Tanaka; Hitoshi Aizawa; Masatoshi Tateno; Esteban Celis
Journal:  Clin Cancer Res       Date:  2006-06-15       Impact factor: 12.531

4.  Lack of effective T-lymphocyte response to the PAX3/FKHR translocation area in alveolar rhabdomyosarcoma.

Authors:  David A Rodeberg; Rebecca A Nuss; Carrie J Heppelmann; Esteban Celis
Journal:  Cancer Immunol Immunother       Date:  2004-11-20       Impact factor: 6.968

5.  Recognition of six-transmembrane epithelial antigen of the prostate-expressing tumor cells by peptide antigen-induced cytotoxic T lymphocytes.

Authors:  David A Rodeberg; Rebecca A Nuss; Sherine F Elsawa; Esteban Celis
Journal:  Clin Cancer Res       Date:  2005-06-15       Impact factor: 12.531

6.  Phase I Trial of Intratumoral Injection of CCL21 Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8+ T-cell Infiltration.

Authors:  Jay M Lee; Mi-Heon Lee; Edward Garon; Jonathan W Goldman; Ramin Salehi-Rad; Felicita E Baratelli; Dörthe Schaue; Gerald Wang; Fran Rosen; Jane Yanagawa; Tonya C Walser; Ying Lin; Stacy J Park; Sharon Adams; Francesco M Marincola; Paul C Tumeh; Fereidoun Abtin; Robert Suh; Karen L Reckamp; Gina Lee; William D Wallace; Sarah Lee; Gang Zeng; David A Elashoff; Sherven Sharma; Steven M Dubinett
Journal:  Clin Cancer Res       Date:  2017-05-03       Impact factor: 12.531

7.  Identification of a broad coverage HLA-DR degenerate epitope pool derived from carcinoembryonic antigen.

Authors:  Lavakumar Karyampudi; Christopher J Krco; Kimberly R Kalli; Courtney L Erskine; Lynn C Hartmann; Karin Goodman; James N Ingle; Matthew J Maurer; Aziza Nassar; Chao Yu; Mary L Disis; Peter J Wettstein; John D Fikes; Melanie Beebe; Glenn Ishioka; Keith L Knutson
Journal:  Cancer Immunol Immunother       Date:  2009-07-21       Impact factor: 6.968

8.  Increased expression of CEA and MHC class I in colorectal cancer cell lines exposed to chemotherapy drugs.

Authors:  Shunroh Ohtsukasa; Satoshi Okabe; Hironori Yamashita; Takehisa Iwai; Kenichi Sugihara
Journal:  J Cancer Res Clin Oncol       Date:  2003-10-15       Impact factor: 4.553

9.  Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma.

Authors:  James L Gulley; Philip M Arlen; Kwong-Yok Tsang; Junko Yokokawa; Claudia Palena; Diane J Poole; Cinzia Remondo; Vittore Cereda; Jacquin L Jones; Mary P Pazdur; Jack P Higgins; James W Hodge; Seth M Steinberg; Herbert Kotz; William L Dahut; Jeffrey Schlom
Journal:  Clin Cancer Res       Date:  2008-05-15       Impact factor: 12.531

Review 10.  Peptide epitope identification for tumor-reactive CD4 T cells.

Authors:  Hiroya Kobayashi; Esteban Celis
Journal:  Curr Opin Immunol       Date:  2008-05-20       Impact factor: 7.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.